Science Market Update

Angelman Syndrome Treatment on Horizon Due to UC Davis Research Grants

Posted by Rebecca Partridge on Mon, Nov 07, 2016

UC Davis Medical Center researchers have recently been awarded several grants to investigate promising treatments for Angleman Syndrome. Dr. David Segal, professor in the Department of Biochemistry and Molecular Medicine, has received over $1.2 million from the Foundation for Angelman Syndrome Therapeutics (FAST) to develop a potential treatment. Joe Anderson, PhD, assistant adjunct professor in the Department of Internal Medicine, received $500,000 from the same organization to pursue a different approach to developing a treatment for the genetic disorder. The university also received a $1.1 million grant from the California Institute for Regenerative Medicine (CIRM) in July, which brings the total for Angelman Syndrome grant funding to nearly $3 million. This puts UC Davis at the forefront of research into the disorder.

Protein_UBE3A_PDB_1c4z.png(Image of UBE3A Protien courtesy of Wikimedia Commons) 

What is Angelman Syndrome?

According to the Angelman Syndrome Foundation it is “a rare neuro-genetic disorder that occurs in one in 15,000 live births. Angelman syndrome is often misdiagnosed as cerebral palsy or autism due to lack of awareness. Characteristics of the disorder include developmental delay, lack of speech, seizures, and walking and balance disorders. Individuals with Angelman syndrome will require life-long care.”

Current research has led scientists to believe that the syndrome is caused by the loss of expression of a protein normally made by the Ube3a gene, which plays a critical role in the nervous system.

How will the new research funding be used to address this issue?

An article for the UC Davis Newsroom states, “Segal, a faculty member at the MIND Institute, is using his grant funding to further develop gene editing technology to reactivate a gene in the brain, known as Ube3a, which is silenced in Angelman syndrome.” His lab has already created a protein that can control gene function and manipulate gene expression. In an earlier study, also funded by FAST, this protein was shown to turn on the affected gene in mouse models of Angelman Syndrome. 

Dr. Segal says, “The generous support from FAST and CIRM is recognition of the innovative molecular therapies being developed at UC Davis for Angelman Syndrome. The collaborative teams to do this work are here, the knowledge experts are here, and now these sponsors have given us the chance to really try and help kids with this disease."

In another research project, Dr. Anderson and his colleagues are seeking to restore Ube3a expression using gene-delivery technology. They hope to accomplish this by genetically modifying blood-forming stem cells so they will express the “wild type form” of the gene. If this is successful, they will then engraft the modified cells so they produce new cells that can deliver the protein to affected neurons. The research will also evaluate the safety and effectiveness of these delivery vehicles in cell cultures as well as animal models of the disease.

“If normal levels of expression of the Ube3a protein could be delivered to affected cells for the life of the patient, regression of the disease may be achievable,” Anderson said.

The third project involves using artificial transcription factors to turn on the gene that’s inactivity causes Angelman syndrome. This CIRM—funded research is studying mesenchymal stem cells as a delivery vehicle for a gene-modifying protein that recognizes and binds to the specific gene sequence related to the syndrome.

Paula Evans, chair and founder of FAST, concluded that due to the dedication of researchers at UC Davis Medical Center, “A cure is no longer a matter of if, but when.”

Upcoming Event at UC Davis Medical Center:


UC Davis Receives $3M in Cancer Research Funding 

UCSD Researchers Receive $5M to Study Type 1 Diabetes

Texas A&M Gains Research Funding to Study Post-Traumatic Epilepsy 

On Wednesday, January 18th, 2017 Biotechnology Calendar Inc. will host the 19th Semiannual BioResearch Product Faire™ at UC Davis Medical Center. Life science professionals are invited to attend the upcoming trade fair for free. For more information and to pre-register, visit the link below.

Researchers Attend  UCDMC Event

This event allows laboratory equipment suppliers to meet face to face with UC Davis researchers and discuss their equipment needs. It is a great place for lab and chemical supply companies to demonstrate their latest products. Those interested in exhibiting should click the link below or call (530) 272-6675 for more information.

Exhibitors  UC Davis Medical Center Event               IMG_0235.jpg 

Tags: Biotechnology vendor show, Biotechnology Vendor Fair, UC Davis - Medical Center, research grants, UC Davis, Bioresearch Grant, angelman syndrome

Subscribe to Company News